Evidence map›Paper›PMID 37991653›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.

Abena Minta, Lucy Rose, Candice Park, Bhuvaneswari Ramaswamy, Daniel Stover, Margaret Gatti-Mays, Mathew Cherian, Nicole Williams, Preeti Sudheendra, Robert Wesolowski and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Cancer-Related Alopecia Risk and Treatment.Current treatment options in oncology · 2025
    Review
  3. Review
  4. Approaches to management of endocrine therapy-induced alopecia in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Abena MintaThe Ohio State University College of Medicine, Columbus, OH, USA.
Lucy RoseThe Ohio State University College of Medicine, Columbus, OH, USA.
Candice ParkThe Ohio State University College of Medicine, Columbus, OH, USA.
Bhuvaneswari RamaswamyDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Daniel StoverDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Margaret Gatti-MaysDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Mathew CherianDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Nicole WilliamsDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Preeti SudheendraDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Robert WesolowskiDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Sagar SardesaiDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Maryam LustbergDepartment of Medical Oncology, Yale Cancer Center, New Haven, CT, USA.
Charles L LoprinziDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Kathryn J RuddyDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Elizabeth Cathcart-RakeDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Stephanie TrovatoDepartment of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Brittany DulmageDepartment of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Brittany.Dulmage@osumc.edu.
The Ohio State University Wexner Medical Center · USMayo Clinic in Arizona · USThe Ohio State University · USYale Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDermatologic adverse events commonly result in the interruption of oncologic treatment, and targeted therapies are the most frequently interrupted class of anticancer agents. Alopecia is a common cutaneous adverse event reported with CK4/6i therapy. Though the clinical characteristics and therapeutic response of EIA have been well documented, few studies have characterized alopecia in patients treated with CDK4/6i.

methodsThis study analyzed a retrospective cohort of 28 breast cancer patients diagnosed with endocrine-induced alopecia (EIA) or CDKiA. Comparative analysis of the clinical characteristics of alopecia and therapeutic response to minoxidil was conducted. Therapeutic response to minoxidil (LDOM or topical [5%] solution or foam) was assessed by both Dean Scale and qualitative clinical improvement by comparison of pretreatment and posttreatment clinical images by single-blinded, board-certified academic dermatologists (ST and BD).

resultsCDKiA was clinically similar to androgenetic alopecia and specific vertex involvement was more common in patients treated with CDK4/6i + ET than endocrine monotherapy (n = 7 [70.0%] vs n = 4 [36.4%]; p = 0.04), respectively. After 4-6 months of minoxidil, there was a moderate to significant qualitative alopecia improvement in 80% of CDKiA patients versus 94.4% of EIA patients. Additionally, superior improvement of mean Dean Score grade was observed in EIA (with change from pre- to posttreatment - 0.44; p = 0.0002).

conclusionCompared to endocrine monotherapy, patients on combination CDK4/6i + ET had greater extent of vertex involvement and were more recalcitrant to minoxidil. The preferential vertex involvement observed in CDKiA suggests that combination therapy with minoxidil and topical antiandrogens with poor systemic absorption should be studied in this setting.

Indexed as

Breast NeoplasmsMinoxidilAdministration, CutaneousAlopeciaCyclin-Dependent Kinase 4FemaleHumansRetrospective StudiesTreatment OutcomeCDK4 protein, humanCyclin-Dependent Kinase 4MinoxidilAlopeciaCDK4/6iEndocrine-induced alopeciaEndocrine therapyMedical dermatologyOncodermatologyOncologySurvivorship

Identifiers

PMID37991653
OpenAlexW4388911633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.